Harvard Bioscience Inc (HBIO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $42.94M
Last updated: Nov 17, 2026 at 11:03 AM ET
Harvard Bioscience Inc (HBIO) Stock Forecast
Analysts expect Harvard Bioscience (HBIO) to earn -$0.62 per share in the fiscal year ending Dec 31, 2026, on revenue of $90.14M. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.92.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 5.8%.
- Fiscal year ending Dec 31, 2026
- -$0.62
- EPS consensus, revenue $90.14M
- Fiscal year ending Dec 31, 2027
- $0.92
- EPS consensus, revenue $95.40M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.62 | -$0.62 to -$0.62 | 1 | $90.14M | $90.10M to $90.18M | 2 |
| Dec 31, 2027 | $0.92 | $0.92 to $0.92 | 1 | $95.40M | $95.00M to $95.80M | 2 |
Quarterly Estimates
The EPS consensus falls from $0.19 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.19 | $0.08 to $0.32 | 4 | $24.96M | $23.91M to $25.73M | 5 |
| Mar 31, 2027 | -$0.01 | -$0.01 to -$0.01 | 1 | $23.50M | $23.50M to $23.50M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.38.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.62 | -$0.38 | -$0.38 | -$0.38 | -$0.38 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.92 | $0.65 | $0.65 | $0.65 | $0.65 | +42.6% |
| Quarter ending Mar 31, 2027 | -$0.01 | -$0.23 | -$0.23 | -$0.23 | -$0.23 | N/A |
Frequently Asked Questions About HBIO
What is the HBIO stock forecast?
Consensus analyst estimates put Harvard Bioscience's EPS at -$0.62 for the fiscal year ending Dec 31, 2026, on revenue of $90.14M.
What EPS do analysts expect from HBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.62, with estimates from -$0.62 to -$0.62 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.92, with estimates from $0.92 to $0.92 from 1 analyst.
What revenue do analysts expect from Harvard Bioscience next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $90.14M, with estimates from $90.10M to $90.18M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $95.40M, with estimates from $95.00M to $95.80M.
How many analysts cover HBIO?
1 analyst estimates EPS for Harvard Bioscience for the fiscal year ending Dec 31, 2026.
HBIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts